🧬 BioMed Pulse · 2026-07-11 02:01 UTC

BIOMED PULSE

July 11, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now reached 1,460 confirmed cases and 452 deaths as of July 1, with CDC issuing a fresh statement on July 10 — the single most urgent global health story of the moment. The overall mood is cautious-to-alarmed: two concurrent active PHEICs (Ebola-BVD and Andes hantavirus), a new Nipah case in India, and early West Nile records in the U.S. make this a crowded threat landscape, tempered by the first-ever treatment trial for Bundibugyo disease now enrolling patients. ^{[1] [2] [3]}

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS (DRC AND UGANDA) — PHEIC

• CDC issued a statement on July 10, 2026, on the ongoing Ebola outbreak caused by Bundibugyo virus spanning DRC and Uganda. ^[1]
• As of July 1, WHO confirmed 1,460 cases and 452 deaths from DRC alone, with cross-border transmission to Uganda ongoing since mid-May. ^[2]
• WHO declared a Public Health Emergency of International Concern (PHEIC) on May 17; the IHR Emergency Committee determined the event does not yet meet the threshold for a pandemic emergency. ^{[4] [5]}
• Africa CDC and WHO jointly launched a continental response plan on June 5 seeking US$ 518 million to support African country preparedness. ^[6]
• WHO issued its first comprehensive clinical management guidelines for filovirus disease (all Ebola and Marburg subtypes) on June 17 in direct response to this outbreak. ^[7]
• The PARTNERS clinical trial opened patient enrolment in DRC on July 2, 2026, as the first-ever scientific trial to identify effective treatments specifically for Bundibugyo virus disease. ^[3]
• WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing on July 2, enabling rapid genetic detection in blood samples. ^[8]
• Enhanced airport Ebola screening that began at Washington Dulles on May 21 expanded to Atlanta Hartsfield-Jackson on May 23. ^{[9] [10]}

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY)

• The fifth WHO Disease Outbreak News report (July 2) on the Andes hantavirus (ANDV) cluster linked to cruise ship M/V Hondius confirmed additional cases since the previous update on May 28.
• The outbreak was first reported to WHO on May 2; original cases presented with severe acute respiratory illness aboard the ship carrying 147 passengers and crew.
• CDC provided multiple hantavirus response briefings through late June 2026, monitoring U.S. traveler exposure.

NIPAH VIRUS — INDIA

• WHO confirmed one laboratory-confirmed Nipah virus (NiV) infection in Kozhikode district, Kerala State, India, announced June 25; the adult male patient developed neurological symptoms on May 30 and was hospitalized June 10.
• Earlier in 2026, two NiV cases were confirmed in healthcare workers in West Bengal (January 30) and one case in Rajshahi Division, Bangladesh (February 6).

WEST NILE VIRUS AND VECTOR-BORNE DISEASE — UNITED STATES

• CDC reported an early and record West Nile virus season as of July 1, urging the public to avoid mosquito bites over the July 4th holiday weekend.
• CDC data from April 2026 showed weekly emergency room visits for tick bites running higher than usual for the season.

MPOX — RECOMBINANT STRAIN

• WHO reported two cases globally of a recombinant mpox strain combining genomic elements of clade Ib and clade IIb monkeypox virus (MPXV), published February 14, 2026; recombination is a known natural process when two viral strains co-infect one individual.

YELLOW FEVER — GLOBAL

• From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission activity in the Americas continued from a 2025 increase into 2026.

AVIAN INFLUENZA A(H9N2) — ITALY

• Italy notified WHO on March 21 of one human H9N2 case in an adult male returning from Senegal, confirmed by next-generation sequencing.

MEASLES — BANGLADESH

• As of April 4, 2026, Bangladesh reported 19,161 suspected measles cases with 2,897 laboratory-confirmed cases across 58 of 64 districts and all eight divisions nationwide.

CANCER PROJECTIONS — WHO GLOBAL ALERT

• WHO reported on July 8 that global new cancer cases are projected to nearly double by 2050, with an estimated 20.6 million new cases and close to 10 million deaths occurring annually today.

🧬 LONGEVITY & AGING

NAD+ RESTORATION FOR AGED BONE REPAIR

• A new study published in Bioactive Materials (June 27) describes a senescent metabolism-modulating hierarchical scaffold that restores NAD+ homeostasis and redox balance, promoting bone repair in aged tissue.
• NAD+ depletion is a key hallmark of cellular senescence; restoring it via a biomaterial scaffold represents a tissue-engineering approach to aging-related bone loss.

KAEMPFEROL FROM MORINGA AND LONGEVITY IN DROSOPHILA

• Research published in Toxicology Reports (June 25) found kaempferol extracted from Moringa oleifera increases longevity and reduces efavirenz-induced functional senescence in Drosophila melanogaster, suggesting a phytochemical pathway to senescence modulation.
• Efavirenz is an antiretroviral drug whose side effects include mitochondrial stress; kaempferol appeared to counteract that cellular aging phenotype.

EMERIN, TAU, AND NEURONAL AGING

• A July 7 paper in Nucleus identified elevated emerin — a nuclear mechanosensitive protein — as a link between nuclear mechanotransduction and tau-induced cytoskeletal remodeling in neurons, a finding relevant to Alzheimer's and other tauopathies.

DELIRIUM AS A BRIDGE FROM INFECTION TO DEMENTIA

• Two companion commentaries in Lancet Healthy Longevity argue that delirium following severe infection may be the missing mechanistic link between acute infectious illness and subsequent dementia, calling for delirium prevention as a dementia-prevention strategy.

INSULIN RESISTANCE, COGNITIVE IMPAIRMENT, AND AGING

• A study in Scandinavian Journal of Primary Health Care (June 23, authors Rotonen et al.) found associations between insulin resistance and lower health-related quality of life in adults with mild cognitive impairment during aging.

HYPERTENSION AND FRAILTY IN OLDER ADULTS — INDIA DATA

• A letter in Blood Pressure (July 7) highlighted data from the Longitudinal Ageing Study in India linking hypertension to increased frailty prevalence among middle-aged and older adults.

MULTIMORBIDITY AND KIDNEY DISEASE MORTALITY

• The NURTuRE-CKD multicentre cohort study (Annals of Medicine, June 23) found that multiple long-term conditions significantly accelerate mortality, progression to kidney failure, and reduce health-related quality of life in chronic kidney disease patients.

TOBACCO AND METABOLIC LIVER DISEASE BURDEN

• A Europe PMC paper published July 3 quantified the global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) attributable to tobacco from 1990 to 2023 and projected worsening trends to 2038.

EXERCISE AND NITRATE SUPPLEMENTATION TRIAL FOR OLDER ADULTS

• ClinicalTrials.gov lists a study (NCT07572266, updated July 10) titled "Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults," targeting aging-related functional decline via dietary nitrate as a co-treatment with exercise, addressing hallmark biological aging processes.

MEDICAL-SOCIAL DETERMINANTS OF HEALTHY LONGEVITY

• A comprehensive analysis published in Problemy Sotsialnoi Gigieny (authors Amonova et al.) reviewed challenges and prevention strategies for achieving healthy longevity through medical and social determinants.

💊 NEW CURES & APPROVALS

NOTE: The openFDA data in today's feed reflects supplemental approvals (SUPPL AP) and one original approval (ORIG AP) for established drugs; no novel first-in-class approvals were recorded in this window. Key items:

UPADACITINIB (RINVOQ LQ) — ABBVIE

• AbbVie received a supplemental approval for upadacitinib (RINVOQ LQ, NDA218347), a JAK1-selective inhibitor used across multiple inflammatory indications including atopic dermatitis and rheumatoid arthritis.

LEVOCARNITINE — BAXTER HEALTHCARE CORP

• Baxter Healthcare Corp received an original approval (ORIG AP) for levocarnitine (ANDA217896), used for carnitine deficiency, particularly in dialysis patients, where deficiency accelerates metabolic decline.

ACYCLOVIR — AUROBINDO PHARMA AND NOVITIUM PHARMA

• Supplemental approvals were recorded for generic acyclovir (antiviral for herpes simplex and varicella-zoster) from two manufacturers: Aurobindo Pharma (ANDA216331) and Novitium Pharma (ANDA212252).

FINASTERIDE — ACCORD HEALTHCARE AND TEVA

• Supplemental approvals for generic finasteride (5-alpha-reductase inhibitor, used for benign prostatic hyperplasia and androgenetic alopecia) were recorded for Accord Healthcare (ANDA090121) and Teva (ANDA076511).

MOMETASONE FUROATE (ELOCON) — ORGANON

• Organon received three supplemental approvals for mometasone furoate topical formulations (NDA019625, NDA019796, NDA019543), a corticosteroid used for inflammatory skin conditions.

🧪 CLINICAL TRIALS

PARTNERS TRIAL — FIRST BUNDIBUGYO VIRUS TREATMENT TRIAL

• The PARTNERS clinical trial opened enrolment in DRC on July 2, 2026, representing the first international scientific effort to evaluate candidate therapeutics specifically for Ebola disease caused by Bundibugyo virus. ^[3]
• WHO convened expert advisory groups on May 28 to assess vaccines and therapeutics for Bundibugyo virus prevention and treatment, feeding directly into PARTNERS trial design.

IL-12 GENETICALLY ENGINEERED MYELOID CELLS — SOLID TUMORS

• NCT07672483 (updated July 10) is testing IL-12 genetically engineered myeloid cells (IL-12 GEMys) in participants with relapsed or refractory solid tumors; the mechanism involves reprogramming tumor-infiltrating myeloid cells to secrete IL-12 and stimulate anti-tumor immunity.

BRINCIDOFOVIR FOR PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

• NCT07511049 (updated July 10) is a pilot study of intravenous brincidofovir as an antiviral for JC virus-caused progressive multifocal leukoencephalopathy (PML), a rare fatal brain infection affecting immunocompromised patients.

177Lu-DOTA-EB-TATE FOR ONCOCYTIC THYROID CANCER

• NCT06991738 (updated July 10) is testing the radioligand 177Lu-DOTA-EB-TATE targeting somatostatin receptors overexpressed on Hurthle cell thyroid cancer, a rare cancer with few existing options.

ADJUVANT NITRATE FOR AGING-RELATED FUNCTIONAL DECLINE

• NCT07572266 (updated July 10) is investigating dietary nitrate as an adjuvant to exercise in older adults, aiming to amplify exercise benefits against hallmark biological aging processes including metabolic and physical impairment.

MULTISENSORY FALLS ASSESSMENT — CATCHU STUDY

• NCT05544760 (updated July 10) is assessing multisensory integration as a quantitative clinical tool for falls risk in aging populations, targeting the visual-somatosensory integration processes that decline with age.

📢 PUBLIC HEALTH

EBOLA FROZEN BLUEBERRIES AND FOOD SAFETY ALERTS

• CDC warned on July 7 of an E. coli outbreak linked to frozen blueberries; consumers are advised not to eat recalled product.

U.S. WITHDRAWAL FROM WHO — COMPLETED JANUARY 2026

• The United States formally completed its WHO withdrawal on January 22, 2026, citing COVID-19 failures and politicization; the U.S. has shifted to bilateral health partnerships.
• Note for readers: this means U.S. federal agencies are no longer receiving WHO coordination benefits for international outbreak response, a structural gap relevant to ongoing Ebola and hantavirus responses.

UNSAFE FOOD MORTALITY — WHO GLOBAL ESTIMATE

• WHO released new estimates on June 3 showing unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide; children under five face nearly three times the illness risk of older age groups.

WORLD SCREWWORM EMERGENCY — CDC EOC ACTIVATED

• CDC activated its Emergency Operations Center in June 2026 for a New World Screwworm (Cochliomyia hominivorax) response — a parasitic fly that can infest open wounds in mammals including humans.

INFANT BOTULISM — NARA ORGANICS FORMULA

• CDC on June 13 urged parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula, linked to an ongoing infant botulism outbreak investigation.

LISTERIA — REQUESÓN/SOFT RICOTTA CHEESE

• CDC warned on June 5 of a Listeria monocytogenes outbreak linked to requesón/soft ricotta cheese.

DRUG-RESISTANT BACTERIA — SHARP U.S. RISE

• A CDC report from September 2025 found a dramatic increase in dangerous drug-resistant bacteria in the United States; the report emphasized the growing antimicrobial resistance threat.

DRUG OVERDOSE DEATHS — CONTINUED DECLINE

• CDC data from May 2025 showed a 27% decrease in drug overdose deaths in the U.S. in 2024, continuing a trend of nearly 24% decline reported in February 2025.

This briefing is informational only and does not constitute medical advice. Sources: CDC Newsroom, WHO Disease Outbreak News, WHO News, openFDA Drugs@FDA, ClinicalTrials.gov, Europe PMC / PubMed.

📎 Sources

1. CDC Statement on Ebola Outbreak in the Democratic Republic of … — CDC Newsroom
2. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
3. Patient enrolment begins in a scientific trial to identify the… — WHO News
4. Epidemic of Ebola Disease caused by Bundibugyo virus in the De… — WHO News
5. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
6. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
7. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
8. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
9. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
10. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260711-02-v24 · 2026-07-11 02:01 UTC · pulse.uzylab.com